Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$8,285 Mln
Revenue (TTM)
$562 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.5 %
ROCE
-10.1 %
P/E Ratio
--
P/B Ratio
24.2
Industry P/E
--
EV/EBITDA
-11.2
Div. Yield
0 %
Debt to Equity
1
Book Value
$--
EPS
$-2.5
Face value
--
Shares outstanding
64,582,200
CFO
$-1,515.22 Mln
EBITDA
$-2,254.51 Mln
Net Profit
$-2,273.72 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Blueprint Medicines Corp (BPMC)
| 46.9 | 26.0 | 39.0 | 23.3 | 38.1 | 11.4 | 13.9 |
|
BSE Sensex*
| 4.0 | -1.2 | 8.0 | 5.3 | 16.6 | 18.9 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Blueprint Medicines Corp (BPMC)
| -5.4 | 110.5 | -59.1 | -4.5 | 40.0 | 48.6 | -28.4 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Blueprint Medicines Corp (BPMC)
|
128.1 | 8,285.0 | 562.1 | -155.7 | -19.3 | -47.5 | -- | 24.2 |
| 50.1 | 8,093.9 | 1,208.8 | 131.7 | 13.4 | 6.3 | 61.9 | 4.0 | |
| 145.3 | 7,417.9 | 4,022.6 | -31.6 | 3.7 | -1.1 | -- | 2.3 | |
| 52.3 | 9,911.0 | 2,828.1 | -1,019.8 | -36.2 | -36.4 | -- | 4.2 | |
| 40.7 | 11,277.9 | 2,298.9 | 643.6 | 35.4 | 29.2 | 18.9 | 5.3 | |
| 53.2 | 6,644.1 | 1,084.3 | 485.4 | 57.0 | 103.8 | 14.4 | 13.8 | |
| 302.7 | 8,650.6 | 2,156.6 | 416.4 | 21.2 | 56.5 | 23 | 14.4 | |
| 25.4 | 10,055.3 | 3,159.0 | -3,357.0 | -76.7 | -30.5 | -- | 1.0 | |
| 127.3 | 12,370.7 | 2,412.6 | 305.8 | 20.5 | 11.6 | 42.3 | 4.9 | |
| 291.7 | 13,016.0 | 2,994.1 | 1,210.7 | 51.4 | 18.8 | 11.5 | 1.9 |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic... mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Address: 45 Sidney Street, Cambridge, MA, United States, 02139 Read more
President, CEO & Director
Ms. Kathryn Haviland
President, CEO & Director
Ms. Kathryn Haviland M.B.A.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Blueprint Medicines Corp (BPMC) stood at $ 1,446 Mln as on 31-Mar-25
The share price of Blueprint Medicines Corp (BPMC) is $128.12 (NASDAQ) as of 18-Jun-2025 16:00 EDT. Blueprint Medicines Corp (BPMC) has given a return of 38.11% in the last 3 years.
Blueprint Medicines Corp (BPMC) has a market capitalisation of $ 8,285 Mln as on 18-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Blueprint Medicines Corp (BPMC) is 24.21 times as on 18-Jun-2025, a 797% premium to its peers’ median range of 2.70 times.
Since, TTM earnings of Blueprint Medicines Corp (BPMC) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Blueprint Medicines Corp (BPMC) and enter the required number of quantities and click on buy to purchase the shares of Blueprint Medicines Corp (BPMC).
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. Address: 45 Sidney Street, Cambridge, MA, United States, 02139
The CEO & director of Ms. Kathryn Haviland. is Blueprint Medicines Corp (BPMC), and CFO & Sr. VP is Ms. Kathryn Haviland M.B.A..
There is no promoter pledging in Blueprint Medicines Corp (BPMC).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,247
|
|
|
1,229
|
|
|
1,130
|
|
|
1,073
|
|
|
1,050
|
|
|
869
|
|
|
808
|
|
|
742
|
|
|
664
|
| Blueprint Medicines Corp (BPMC) | Ratios |
|---|---|
|
Return on equity(%)
|
-47.53
|
|
Operating margin(%)
|
-19.26
|
|
Net Margin(%)
|
-27.7
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Blueprint Medicines Corp (BPMC) was $0 Mln.
$-0.11
(
